Drug Detail:Fedratinib (systemic) (monograph) (Inrebic)
Drug Class:
Fedratinib Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the use of fedratinib during breastfeeding. Most sources recommend that mothers not breastfeed while taking fedratinib. An alternate drug is preferred, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be withheld at least 1 month after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
(Rheumatoid Arthritis) Adalimumab, Certolizumab Pegol, Etanercept, Infliximab, Tocilizumab
Substance Identification
Substance Name
Fedratinib
CAS Registry Number
936091-26-8
Drug Class
Breast Feeding
Lactation
Enzyme Inhibitors
Protein Kinase Inhibitors
Tyrosine Kinase Inhibitors
Signal Transduction Inhibitors
Janus Kinase Inhibitors
JAK Inhibitors
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification